Somewhat Positive News Coverage Somewhat Unlikely to Impact Immune Design Corp. (IMDZ) Stock Price
Media stories about Immune Design Corp. (NASDAQ:IMDZ) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immune Design Corp. earned a news impact score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.3917686756558 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Biotech Digest – IMDZ Reports Data, JNJ Terminates Collaboration (talkmarkets.com)
- Immune Design to Present at Upcoming Investor Conferences in September (finance.yahoo.com)
- Interim data positive for Immune Design’s prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5% (seekingalpha.com)
- Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress (finance.yahoo.com)
IMDZ has been the topic of a number of research reports. ValuEngine upgraded shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Jefferies Group LLC restated a “buy” rating and set a $18.00 target price on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, May 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Immune Design Corp. currently has a consensus rating of “Buy” and an average price target of $14.50.
Immune Design Corp. (NASDAQ IMDZ) opened at 10.05 on Thursday. The firm’s market capitalization is $257.47 million. The firm’s 50-day moving average is $9.79 and its 200-day moving average is $7.71. Immune Design Corp. has a 52-week low of $4.50 and a 52-week high of $13.05.
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. On average, equities analysts expect that Immune Design Corp. will post ($2.39) earnings per share for the current year.
In other news, Director Lewis W. Coleman acquired 8,000 shares of the firm’s stock in a transaction dated Friday, July 7th. The stock was purchased at an average price of $9.27 per share, for a total transaction of $74,160.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $370,800. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lewis W. Coleman acquired 12,000 shares of the firm’s stock in a transaction dated Tuesday, July 11th. The shares were purchased at an average price of $9.05 per share, with a total value of $108,600.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $362,000. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 30,000 shares of company stock valued at $272,760. Corporate insiders own 42.90% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/07/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-immune-design-corp-imdz-stock-price.html.
Immune Design Corp. Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.